gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Synovial sarcoma, X breakpoint 2

The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X;18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: SYT-SSX, POLYMERASE, CAN, HAD, NY-ESO-1
Papers using SSX2 antibodies
Surface passivation of a microfluidic device to glial cell adhesion: a comparison of hydrophobic and hydrophilic SAM coatings
Mayama Shigeki et al., In Journal of Nanobiotechnology, 2001
... Ltd., Saitama, Japan), XPS (SSX-100, Surface Science Instruments, Mountain View, CA), and FT-IR (Spectrum One, PerkinElmer, Waltham, MA).
Papers on SSX2
[Synovial sarcoma in children and adolescents].
Corradini et al., Nancy, France. In Bull Cancer, Feb 2016
translocation resulting in two chimeric fusion genes SYT-SSX1 and SYT-SSX2, confirming histological diagnosis.
The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.
Yoshida et al., Tokyo, Japan. In Hum Pathol, Jan 2016
Synovial sarcoma is a malignant mesenchymal neoplasm of uncertain histogenesis, characterized by a specific SS18-SSX fusion.
Pulmonary Metastases Exhibit Epigenetic Clonality: Implications for Precision Cancer Therapy.
Schrump et al., Bethesda, United States. In Ann Thorac Surg, Nov 2015
Quantitative reverse transcription polymerase chain reaction techniques were used to evaluate expression levels of cancer-testis (CT) genes (NY-ESO-1, MAGE-A3, MAGE-A9, MAGE-A12, GAGE1, CT-45, SSX-1, and SSX-2), tumor suppressor (TS) genes (p16 and RASSF1A), and genes encoding epigenetic modifiers (DNMT1, DNMT3A, DNMT3B, EZH2, EED, and SUZ12), aberrantly expressed in human malignant diseases.
β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition.
Jones et al., Salt Lake City, United States. In Oncotarget, Oct 2015
β-catenin is a master regulator in the cellular biology of development and neoplasia.
Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Toretsky et al., Washington, D.C., United States. In Cancer Metastasis Rev, Sep 2015
Patients afflicted with synovial sarcoma share the fate of other translocation positive sarcomas; the driver mutation for this cancer is known, yet no means to target the fusion protein SS18-SSX directly exist.
Intratubular germ cell neoplasia of the testis: a brief review.
Akhtar et al., Riyadh, Saudi Arabia. In Adv Anat Pathol, May 2015
The tumor cells manifest many of the proteins normally expressed by mature sperms such as VASA, SSX2, and occasionally OCT2.
[About a rare tumor of the kidney: Malignant mixed epithelial and stromal tumor].
Kchir et al., Tunisia. In Prog Urol, May 2015
Analysis by reverse transcriptase polymerase chain reaction (RT-PCR) failed to identify the SYT-SSX1 or SYT-SSX2 fusion transcripts characteristic of synovial sarcoma.
Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.
Ladanyi et al., Vancouver, Canada. In Cancer Discov, Feb 2015
UNLABELLED: Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t(X,18; p11,q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal repression domains of SSX1 or SSX2.
Cancer/testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells.
Zhou et al., Suzhou, China. In Curr Pharm Des, 2014
The can cer-testis antigens, such as SSX, MAGE-D4B, CAGE, piwil2, and CT45A1, upregulate EMT and metastatic genes, promoting EMT and tumor dissemination.
SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Toguchida et al., Kyoto, Japan. In Plos One, 2014
In the present study, we examined the effects of the cellular context on the function of the synovial sarcoma (SS)-specific fusion protein, SS18-SSX, using human pluripotent stem cells (hPSCs) containing the drug-inducible SS18-SSX gene.
Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
Crabtree et al., Stanford, United States. In Cell, 2013
To investigate the underlying mechanism, we studied human synovial sarcoma (SS), in which transformation results from the translocation of exactly 78 amino acids of SSX to the SS18 subunit of BAF complexes.
Synovial sarcoma mechanisms: a series of unfortunate events.
Svejstrup, London, United Kingdom. In Cell, 2013
Human synovial sarcoma is caused by a chromosome translocation, which fuses DNA encoding SSX to that encoding the SS18 protein.
Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling.
Wang et al., Nanjing, China. In Int J Oncol, 2012
The regulation of estrogen receptor alpha signaling by target proteins of SSX2 may explain the metastatic potential of breast cancer cells.
Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.
Eid et al., Nashville, United States. In Oncogene, 2012
the initial events that likely occur when SYT-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation
Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Nielsen et al., Vancouver, Canada. In Cancer Cell, 2012
Synovial sarcoma is a translocation-associated sarcoma where the underlying chromosomal event generates SS18-SSX fusion transcripts.
Targeting epigenetic misregulation in synovial sarcoma.
Meltzer et al., Bethesda, United States. In Cancer Cell, 2012
Like many sarcomas, synovial sarcoma is driven by a characteristic oncogenic transcription factor fusion, SS18-SSX.
A conditional mouse model of synovial sarcoma: insights into a myogenic origin.
Capecchi et al., Salt Lake City, United States. In Cancer Cell, 2007
Synovial sarcoma is an aggressive soft-tissue malignancy marked by a unique t(X;18) translocation leading to expression of a chimeric SYT-SSX fusion protein.
Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.
Yang et al., Qingdao, China. In Life Sci, 2006
Two kinds of cancer-testis antigen, SSX-2 and SSX-5 showed high-specific and high-frequent expression in hepatocellular carcinoma tissues, but neither of them could be detected in adjacent non-HCC tissues.
Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma.
Nilbert et al., Lund, Sweden. In Int J Cancer, 2006
demonstrate differentially expressed genes for the 2 major gene fusion variants in SS, chromosome 18 synovial sarcoma (SS18)/SSX1 and SS18/SSX2, and thereby suggest that these result in different downstream effects
Molecular diagnosis of synovial sarcoma: RT-PCR detection of SYT-SSX1/2 fusion transcripts in paraffin-embedded tissue.
Dundr et al., Praha, Czech Republic. In Med Sci Monit, 2005
RT-PCR detection of SSX2 in paraffin-embedded tissue allowed for molecular diagnosis of synovial sarcoma.
share on facebooktweetadd +1mail to friends